Drugs / LY2886721
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT01807026 | Mar → May 2013 | Alzheimer disease | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01775904 | Feb → May 2013 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01534273 | Feb → Jul 2012 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01367262 | Jun → Jul 2011 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01227252 | Dec 2010 → Apr 2011 | Alzheimer disease | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01133405 | Jun → Oct 2010 | Alzheimer disease | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01561430 | Mar 2012 → Aug 2013 | Alzheimer disease | Eli Lilly and Company | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2013-06-13 | Eli Lilly and Company | Results Lilly Voluntarily Terminates Phase II Study for LY2886721, a Beta Secretase Inhibitor, Being Investigated as a Treatment for Alzheimer's Disease lilly.com ↗
Eli Lilly and Company (NYSE: LLY) today announced it has stopped its Phase II study (BACC) for LY2886721, a beta secretase (BACE) inhibitor being investigated as a once daily treatment for its potential to slow the progression of Alzheimer's disease. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2013-06-13 | Eli Lilly and Company | Lilly Voluntarily Terminates Phase II Study for LY2886721, a Beta Secretase Inhibitor, Being Investigated as a Treatment for Alzheimer's Disease lilly.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY2886721 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01534273 ↗ |
| Modality | Small molecule | — CHEMBL2396989 ↗ |
| Route | Oral | “Single (7 milligram (mg), 15 mg, 25 mg, 35 mg) doses of LY2886721 administered orally in up to three of three study periods” NCT01133405 ↗ |